The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).

Yoshitaka  Honma

Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai/Roche; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Teijin Pharma

Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Loxo (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst); Taiho Pharmaceutical (Inst)

Yukinori  Kurokawa

Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; MC Medical; Medtronic; Nippon Kayaku; Olympus; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Yakult Honsha

Research Funding - Intuitive Surgical (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)

Akira  Sawaki

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Pfizer

Research Funding - Taiho Pharmaceutical (Inst)

Yoichi  Naito

Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical

Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Chugai Pharma; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Lilly; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda

Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Lilly; Pfizer; Taiho Pharmaceutical

Shiro  Iwagami

Research Funding - Taiho Pharmaceutical (Inst)

Hideo  Baba

Honoraria - Taiho Pharmaceutical

Research Funding - Asahi Kasei; Chugai Pharma (Inst); Johnson & Johnson K.K.; Lilly Japan; MSD K.K (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)

Yoshito  Komatsu

Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha

Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha

Toshirou  Nishida

Honoraria - EA Pharma; Otsuka; Pfizer

Toshihiko  Doi

Honoraria - Abbvie; Astellas Pharma; Bristol-Myers Squibb Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical

Consulting or Advisory Role - Abbvie; Amgen; Bayer; Boehringer Ingelheim; Daiichi Sankyo; MSD; Novartis; Otsuka; Rakuten Medical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda

Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)